Sara Tolaney, MD, MPH; Rupert Bartsch, MD; Carmen Criscitiello, MD, PhD

In recent years, there have been significant advancements in the treatment of HER2+ metastatic breast cancer (MBC), broadening the array of available therapeutic options. However, navigating the complexities of selecting the optimal sequence for HER2 targeted therapies remains challenging.

Join our distinguished faculty Drs Sara Tolaney, Rupert Bartsch, and Carmen Criscitiello for an engaging symposium, where they delve into the latest guideline recommendations and treatment data for HER2+ MBC. Through case-based scenarios, our experts explore the clinical implementation of treatment sequencing, particularly for patients with disease progression after T-DXd and those with CNS involvement.